Graham Campbell & Michelle Baker Jones | “Psychedelic Therapy with DMT”

Graham and Michelle will share their experience of working with DMT-assisted psychotherapy as a potential treatment for depression. They will describe the Phase I and IIa trials and share some of the experiences of healthy volunteers and patients in the trials. They hope to provide an insight into the participant journey through the trials and the broad nature of their psychedelic experiences. They will present the main findings from both trials whilst offering reflection on their experience of working with DMT as a potential therapeutic tool.

____

Michelle Baker Jones

Michelle is an integrative psychotherapeutic counsellor based in London, where she has a private practice. She has been a member of Imperial College’s Psychedelic Research Group since 2015. Michelle was a lead guide on Imperial College’s randomised controlled trial (Psilodep 2) comparing psilocybin to escitalopram in the treatment of depression.

She has recently been working as a lead therapist for Small Pharma’s clinical trials with DMT-assisted therapy for depression. This was originally a collaboration between Small Pharma and Imperial College London. She co-designed the Beckley Academy Foundations to Psychedelic-Assisted Therapy training course. Michelle has contributed to the development of a therapist training programme for the DMT trials, having co-produced a psychedelic therapy framework for working with DMT.

Michelle offers individual psychedelic integration for people who are struggling to process psychedelic experiences. She co-facilitates the psychedelic integration specialist interest group for The Institute of Psychedelic Therapy, drawing on her experience of facilitating integration groups over the past five years.

www.mbjcounselling.co.uk

https://www.imperial.ac.uk/psychedelic-research-centre/about-the-centre-and-cippres/people/

Graham Campbell

Graham worked in NHS mental health services for 15 years; eight of those years as a consultant psychiatrist in a psychiatric hospital in Brighton & Hove. He has an MSc in Neuroscience from Kings College London and trained with the Imperial College Psychedelic Research Group to work as an assistant guide on the psilocybin vs escitalopram depression trial (Psilodep 2).

He has helped organise and facilitate psychedelic integration groups in Brighton since 2019 and has worked as an associate editor for a special edition of Frontiers in Psychiatry on the potential clinical application of psychedelics. He is a member of the Advisory Council with The Institute of Psychedelic Therapy and co-chairs Academic Circle groups for IPT members/affiliates.

In 2020, he left the NHS to work full-time as a trial psychiatrist and psychedelic guide for Small Pharma’s DMT-assisted psychotherapy trials for depression. Phase I and Phase IIa trials have now been completed. Graham has contributed to the development of a therapist training programme for the DMT trials, having co-produced a psychedelic therapy framework for working with DMT.

He also works as an advisor and writer for Lumenate; a company that turns your phone into a strobe light for inducing altered states of consciousness. He is a mentor for the MIND Foundation augmented psychotherapy training programme and works in private psychiatry practice in Brighton.

Please note: Tickets are non-refundable. You will receive an automated email with the event zoom link immediately after booking, please keep the email accessible for the day. We will make the recording available for ticket holders the Monday week after the event and it will remain available to watch for two weeks after.